Sustained concentrations of active compound were maintained in vitro and in vivo for an oral and a parenteral dosage form respectively. The vehicle of a oral dosage form was modified and the molecular structure of a parenteral dosage form was modified. An oral dosage form was tested in vitro using dissolution apparatus. A parenteral dosage form was tested in vivo using rats. A new oral suspension dosage form for acetylsalicylic acid was compared to two controlled release forms and two immediate release dosage forms which are currently commercially available. A parenteral thrombomodulin analogue conjugated to polyethylene glycol was compared to the unconjugated thrombomodulin analogue. In each case the goal was to maintain sustained concentrations of active compound. / Graduation date: 1991

No description available.

Thesis--University of Wisconsin--Madison. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 170-175).

Class of 2005 Abstract / Objectives: The purpose of this study is to conduct a structured literature search and review of published studies or case reports to evaluate the scientific validity of the association between the use of aspirin in children and the development of Reye’s syndrome exists. Methods: In this descriptive study to evaluate the literature, a Medline online database (1966 to April 2005) literature review was conducted with the purpose of identifying studies and case reports involving the association between aspirin and Reye’s Syndrome. Information examined from the various articles included: type of study, method of data analysis, viral diagnosis, confirmation of diagnostic accuracy, number of patients, age range of patients, other diseases considered, and p values/Odds ratios if available. Results: Of the eight true case-control studies analyzed (the additional case-control study was modified), seven supported the association between aspirin and Reye’s Syndrome with statistically significant differences found between cases and controls (a p- value of < 0.05 or an OR of at least 16). Only one case-control study found no stat istically significant association between the use of aspirin and the development of Reye’s Syndrome. Multiple discrepancies and methodological problems are discussed in detail. Implications: Based on available information, the FDA acted appropriately in 1986. However, aspirin has not been shown to cause Reye’s Syndrome.

No description available.

No description available.

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).

Yes / In recent years, the reports on using nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer prevention and treatment have been on the rise. In 2017, the US Preventive Services Working Group issued primary prevention guidelines on the use of NSAIDs, especially aspirin, for cardiovascular disease and colorectal cancer, and formally established the role and status of aspirin in cancer prevention. However, the mechanism of NSAIDs on preventing cancer is still not clear. In this paper, the progress of the application of NSAIDs, especially aspirin, in the prevention and treatment of tumors in recent years is summarized, and new ideas and directions for the follow-up study are also discussed.

Thesis (M.S.)--University of Michigan, 1979.

Thesis (M.S.)--University of Michigan, 1979.